This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Elevated autoantibodies against incretin hormones may indicate poorer outcomes in diabetes, highlighting potential for new ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Say local manufacturing improves convenience of long-term therapy, stabilises supply chains and lowers prices.

A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management drugs semaglutide and tirzepatide that help suppress appetite, according to ...

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain ...